Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography–mass spectrometry

A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS

“…Over the last decade, a rising number of DBS assays for different classes of drugs have been reported. So far, antidiabetics, immunosuppressants, analgesics, anti-HIV drugs, antihypertensive drugs, antimicrobial agents, anti-epileptics, and the iron chelator deferasirox have been included [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. Among the antidepressants, a DBS assay for analysis of IMP has previously been described as well as for the SSRIs fluoxetine, reboxetine, and paroxetine, and for the atypical antidepressant venlafaxine [26][27][28].…”

Antineoplastic drugs and their analysis: a state of the art review

“…617 Blood sample analysis on blotting paper was particularly useful in the case of mTOR inhibitors by facilitating the collection and processing of the sample prior to LC-MS analysis. [618][619][620][621][622] Under such conditions, concentrations in the order of ng mL −1 were detected. It can be noted that MS detection of mTOR inhibitors was mainly performed via adducts formation including sodium adducts 601,602 or ammonia adducts 623,624,625 because of the neutral character of these molecules.…”

Mass spectrometry of blood low-molecular fraction as a method for unification of therapeutic drug monitoring

“…Для некоторых лекарственных препаратов этот коэффициент был получен эмпирическим путем и, как правило, близок к 1 (от 0,84 до 1,13 [57,[62][63][64][65][66][67][68][69][70]). Следует также отметить, что для лекарственных веществ, для которых эмпирически коэффициент пересчета не установлен, можно применять формулу пересчёта, известную как поправку на гематокрит [61,[71][72][73][74][75][76][77]. Таким образом, при использовании эмпирически полученных коэффициентов или соответствующих формул, возможно применение существующих фармакокинетических моделей, созданных с использованием венозной крови, при ТЛМ с использованием капиллярной крови, в том числе и при пм-ТЛМ.…”